NCT07428135Not yet recruiting
Heart Failure Efficacy and Research Trial (HEART) Platform
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The Heart Failure Efficacy and Research Trial (HEART) Platform is a multicenter, randomized platform study designed to improve outcomes for patients with heart failure through the simultaneous and sequential evaluation of multiple interventions across the spectrum of heart failure.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 15 Jan 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Mar 2036
- Lead sponsor
- University of Alberta
- Diseases
- Heart failure
- NCT number
- NCT07428135
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 1 Oct 2026 to the primary completion date, 31 Mar 2036
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Not eligible for assignment to either HEART platform state (State 1 or State 2).
- Presence of conditions or circumstances that, in the investigator's opinion, would make study participation unsafe or not feasible (e.g., inability to comply with study procedures or follow-up).
- Does not meet the eligibility requirements for any active HEART Platform domain.
- Additional inclusion and exclusion criteria apply for each individual HEART Platform domain and will be specified in the relevant domain protocol(s).
Other
- Participants will be excluded if any of the following apply:
- Inability to provide informed consent (and no legally authorized representative available when applicable).
- Any domain-specific exclusion criteria applicable to the intervention/domain(s) for which the participant would otherwise be eligible.
Who the study is looking for
- Participants are eligible for inclusion if they meet all of the following:
- Age ≥18 years (or legal age of majority in participant's country of residence).
- Diagnosis of heart failure, and eligible to be classified into one of the HEART platform states at the time of randomization:
- State 1: Worsening Heart Failure (WHF): currently hospitalized for acute decompensated heart failure or emergency department patients requiring intravenous therapy for heart failure; OR
- State 2: Ambulatory Heart Failure: stable outpatients with established heart failure diagnosis, receiving ongoing HF management and without HF hospitalization within the prior 30 days.
- Able and willing to provide written informed consent (or consent via a legally authorized representative, where applicable).
- Meets all applicable domain-specific eligibility criteria for at least one active HEART Platform domain at the time of screening/randomization.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.